The GLP-1 'companion nutrition' race draws in Nestle, supplement makers and pharma

Food, supplement and pharmaceutical companies are competing to build a new "companion nutrition" business around GLP-1 drugs, targeting the practical side effects of eating much less: lower protein intake, constipation and gaps in vitamins and minerals ^[1]. Nestlé, whose Health Science division already runs a GLP-1 nutrition platform built on brands like Garden of Life, Boost, Nature's Bounty, Nuun and Vital Proteins, is now using AI to speed up research and product development in this space ^[1]. About 11% of U.S. adults currently take GLP-1 medications for weight loss, according to a Gallup survey of 5,065 U.S. adults conducted in late May and early June 2026 ^[1].

The market opportunity is large. Morgan Stanley projects 15% of the U.S. population will be taking GLP-1 drugs by 2035, and JP Morgan estimates food and beverage industry revenue losses could exceed $30 billion by 2030 as people eat less ^[2]. PwC estimates 20% of U.S. households now include someone taking these drugs ^[2]. NielsenIQ data cited in the reporting show that after roughly a year on GLP-1s, consumers buy less pizza (down 15%), potato chips (down 8%) and bacon (down nearly 10%), while purchases of beef, yogurt, strawberries and Brussels sprouts have risen by double digits, and foods with 20 grams of protein per serving are up nearly 20% among long-term users ^[2].

Industry watchers describe a tug-of-war over who owns this space. Scott Dicker of SPINS said supplement brands were first to spot the need, but that entry by companies like Nestlé could expand the overall market rather than simply take share from smaller players, even as it raises competitive pressure on brands whose main pitch is GLP-1 positioning ^[1]. Separately, biosolutions maker Novonesis and Novo Nordisk announced a partnership in 2025 to study whether microbiome-targeted supplements might enhance the effectiveness of GLP-1 weight-loss medications ^[1].

Experts quoted in the reporting caution that the science behind many of these products is uneven. Kantha Shelke of Johns Hopkins University said protein and muscle preservation have the strongest scientific rationale, since GLP-1 drugs can lead people to eat less protein overall, and increasing protein intake may help support lean mass, particularly alongside resistance training ^[1]. But she said other claims are weaker: collagen products marketed around "Ozempic face" have no evidence that consuming collagen restores lost facial fat or tightens loose skin, because facial fat loss is not caused by a collagen deficiency ^[1]. Shelke also said many companies are "merely relabeling" existing products for GLP-1 users rather than reformulating them for the specific nutritional constraints these consumers face ^[1].

Why it matters for patients

None of the products described in this reporting — high-protein foods, fiber blends, micronutrient supplements or muscle-support formulas — has been shown in randomized controlled trials to improve outcomes for people taking GLP-1 medications ^[1]. The marketing is built around real, documented consequences of eating much less food, such as lower protein intake and reduced consumption of a broad range of nutrients, but experts note that these needs are not necessarily unique to GLP-1 users and that many marketed solutions predate the GLP-1 trend ^[1]. Patients considering these companion products are, in effect, evaluating consumer goods positioned around a medical experience, not medical treatments themselves. Sensory changes some GLP-1 users report, including foods tasting different, appear to reflect shifts in food preference and appetite rather than impaired taste function, according to Shelke, which means products claiming to "fix" taste changes are addressing a different problem than the one many companies describe ^[1].

What happens next

Analysts expect the market to keep evolving. Dicker said the "GLP-1 companion" label may eventually fade as these products get absorbed into broader wellness categories like protein, fiber, probiotics and hydration, since consumers ultimately shop for benefits like satiety and digestive wellness rather than for the mechanism behind a drug ^[1]. Shelke said success will likely favor companies that reformulate products specifically for GLP-1 users' changing nutritional needs, rather than those that simply relabel existing items ^[1]. No dated regulatory or clinical milestones for this product category were included in the sources reviewed.